L Simms
Overview
Explore the profile of L Simms including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
310
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wieczorek R, Phillips G, Czekala L, Trelles Sticken E, OConnell G, Simms L, et al.
Toxicol In Vitro
. 2020 May;
66:104866.
PMID: 32353510
The use of electronic vaping products (EVPs) continues to increase worldwide among adult smokers in parallel with accumulating information on their potential toxicity and relative safety compared to tobacco smoke....
2.
Syrigos K, Vansteenkiste J, Parikh P, von Pawel J, Manegold C, Martins R, et al.
Ann Oncol
. 2009 Oct;
21(3):556-561.
PMID: 19828561
Background: Baseline patient and disease characteristics are investigated in non-small-cell lung cancer (NSCLC) in an effort to predict response to treatment and optimize patients' outcomes. Histology has recently been identified...
3.
Simren M, Simms L, DSouza D, Abrahamsson H, Bjornsson E
Aliment Pharmacol Ther
. 2003 Jan;
17(2):279-87.
PMID: 12534414
Background: Irritable bowel syndrome patients demonstrate colonic hypersensitivity after duodenal lipid infusion. Aim: To investigate the role of 5-hydroxytryptamine-3 (5-HT3) receptors in this sensory component of the gastrocolonic response in...
4.
Mori Y, Yin J, Rashid A, Leggett B, Young J, Simms L, et al.
Cancer Res
. 2001 Aug;
61(16):6046-9.
PMID: 11507051
Coding region frameshift mutation caused by microsatellite instability (MSI) is one mechanism contributing to tumorigenesis in cancers with MSI in high frequency. Mutation of TGFBR2 is one example of this...
5.
Simms L, Steinhart A
Cochrane Database Syst Rev
. 2001 May;
(1):CD002913.
PMID: 11279777
Objectives: The primary objective was to precisely derive an estimate of the efficacy of oral budesonide for the maintenance of remission in Crohn's disease. Search Strategy: Medline 1966-September 2000 was...
6.
DSouza D, Dimmitt D, Robbins D, Nezamis J, Simms L, Koch K
J Clin Pharmacol
. 2001 Apr;
41(4):455-8.
PMID: 11304903
Lotronex (alosetron hydrochloride) is a 5-HT3 receptor antagonist indicated for the treatment of irritable bowel syndrome (IBS) in females whose predominant bowel habit is diarrhea. Alosetron is extensively metabolized by...
7.
DSouza D, Levasseur L, Nezamis J, Robbins D, Simms L, Koch K
J Clin Pharmacol
. 2001 Apr;
41(4):452-4.
PMID: 11304902
Lotronex (alosetron hydrochloride) is a 5-HT3 receptor antagonist indicated for the treatment of irritable bowel syndrome (IBS) in females whose predominant bowel habit is diarrhea. Alosetron is extensively metabolized by...
8.
Iino H, Simms L, Young J, Arnold J, Winship I, Webb S, et al.
Gut
. 2000 Jun;
47(1):37-42.
PMID: 10861262
Background And Aim: Hereditary non-polyposis colorectal cancer (HNPCC), as its name implies, is associated with few adenomas, and the early evolution of colorectal neoplasia is poorly understood. In this study...
9.
Borgaonkar M, MacIntosh D, Fardy J, Simms L
Cochrane Database Syst Rev
. 2000 May;
(2):CD000299.
PMID: 10796524
Objectives: To evaluate the effects of anti-tuberculous therapy for the maintenance of remission in patients with Crohn's disease. Search Strategy: We searched the Inflammatory Bowel Disease Trials Register, the Cochrane...
10.
Souza R, Yin J, Smolinski K, Zou T, Wang S, Shi Y, et al.
Cancer Res
. 1997 Jun;
57(12):2350-3.
PMID: 9192806
The E2F group of transcription factors transactivates genes that promote progression through the G1-S transition of the cell cycle. Members of the retinoblastoma (Rb) family of proteins bind to E2Fs...